Development of disease-modifying drugs for frontotemporal dementia spectrum disorders

Topic: Risk, prevention and care in population studies

Frontotemporal dementia (FTD) encompasses a spectrum of clinical syndromes characterized by progressive executive, behavioural and language dysfunction. The various FTD spectrum disorders are associated with brain accumulation of different proteins: tau, the transactive response DNA binding protein of 43 kDa (TDP43), or fused in sarcoma (FUS) protein, Ewing sarcoma protein and TATA-binding protein-associated factor 15 (TAF15) (collectively known as FET proteins). Approximately 60% of patients with FTD have autosomal dominant mutations in C9orf72, GRN or MAPT genes. Currently available treatments are symptomatic and provide limited benefit. However, the increased understanding of FTD pathogenesis is driving the development of potential disease-modifying therapies. Most of these drugs target pathological tau - this category includes tau phosphorylation inhibitors, tau aggregation inhibitors, active and passive anti-tau immunotherapies, and MAPT-targeted antisense oligonucleotides. Some of these therapeutic approaches are being tested in phase II clinical trials. Pharmacological approaches that target the effects of GRN and C9orf72 mutations are also in development. Key results of large clinical trials will be available in a few years. However, clinical trials in FTD pose several challenges, and the development of specific brain imaging and molecular biomarkers could facilitate the recruitment of clinically homogenous groups to improve the chances of positive clinical trial results.

Key findings

• The various FTD spectrum disorders are associated with brain accumulation of different proteins: tau, the transactive response DNA binding protein of 43 kDa (TDP43), or fused in sarcoma (FUS) protein, Ewing sarcoma protein and TATA-binding protein-associated factor 15 (TAF15) (collectively known as FET proteins).
• Key results of large clinical trials will be available in a few years.
• However, clinical trials in FTD pose several challenges, and the development of specific brain imaging and molecular biomarkers could facilitate the recruitment of clinically homogenous groups to improve the chances of positive clinical trial results.

Study details

• Evidence strengthLow

Read the original

• DOI: 10.1038/s41582-020-0330-x
• PubMed: 32203398
• Original source →

Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.

@article{panza2020-32203398,
  author  = {Panza, F. and Lozupone, M. and Seripa, D. and Daniele, A. and Watling, M. and Giannelli, G. and Imbimbo, B. P.},
  title   = {{Development of disease-modifying drugs for frontotemporal dementia spectrum disorders}},
  journal = {Nature reviews. Neurology},
  year    = {2020},
  doi     = {10.1038/s41582-020-0330-x},
  pmid    = {32203398},
  url     = {https://doi.org/10.1038/s41582-020-0330-x}
}

Related studies in Clinical safety

• Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup Alzheimer s & Dementia · 2011-07-01 · usefulness score 55/100
• Alzheimer's neurofibrillary pathology and the spectrum of cognitive function: findings from the Nun Study Annals of neurology · 2002-05-01 · usefulness score 55/100
• The spectrum of behavioral changes in Alzheimer's disease Neurology · 1996-01-01 · usefulness score 47/100
• Homozygosity for the C9orf72 GGGGCC repeat expansion in frontotemporal dementia Acta neuropathologica · 2013-07-02 · usefulness score 43/100
• Dysphagia in patients with frontotemporal lobar dementia Archives of neurology · 2007-01-01 · usefulness score 43/100
• Behaviour in frontotemporal dementia, Alzheimer's disease and vascular dementia Acta neurologica Scandinavica · 2001-06-01 · usefulness score 36/100

Also tagged “bodies”

1,017 studies in the library carry the topic tag “bodies”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,017 tagged studies.

• A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease American journal of human genetics · 2011-07-01 · usefulness score 52/100 · Brain tissue and pathology
• Pathological combinations in neurodegenerative disease are heterogeneous and disease-associated Brain : a journal of neurology · 2023-06-01 · usefulness score 56/100 · Caregiving
• Dementia as the most common presentation of cortical-basal ganglionic degeneration Neurology · 1999-12-01 · usefulness score 47/100 · Disparities

Similar studies

• Treatment of frontotemporal dementia 2014 · Digital health tools
• The epidemiology of frontotemporal dementia 2013 · Disparities
• Frontotemporal dementia 2005 · Lewy body dementia
• Frontotemporal dementia 2015 · Getting a diagnosis
• Advances in understanding the molecular basis of frontotemporal dementia 2012 · Disparities
• Recent advances in the genetics of frontotemporal dementia 2019 · TREM2 and immune genetics

More on Clinical safety

• A review that covers this ground At the extreme end of the psychoneuroimmunological spectrum: delirium as a maladaptive sickness behaviour response Brain, behavior, and immunity · 2012-08-03 · usefulness score 36/100
• Newest in this subject Short-Horizon Metrics and the Persistence of Capacity-Debiting Practices in Nursing Homes Preprints.org · 2026-10-13 · Preprint — not yet peer-reviewed · usefulness score 16/100
• Newest in this subject Expert-Derived Components of Person-Centred Nursing Intervention for People with Dementia and/or Cognitive Impairment in a Hospital Experiencing Distress Research Square · 2026-09-29 · Preprint — not yet peer-reviewed · usefulness score 16/100

See all studies in Clinical safety →